Zepbound is available now!

Zepbound, the newest injectable weight-loss medication just approved by the FDA, is based on the diabetes medication Mounjaro. The generic name for this drug is tirzepatide. This medication has some similarity to Wegovy, which was the first of these meds to be approved for weight loss, as it is in the class of GLP-1 receptor agonists.  Unlike Wegovy, though, Zepbound also interacts with the GIP receptor, which further helps with reducing hunger and portion size.  Two studies done thus far show the potential for tirzepatide to provide better with loss when comparing the two drugs.

Zepbound is a once-weekly injection that comes in a simple-to-use pen that results in minimal discomfort.  When combined with a healthy diet and exercise, these medications can result in significant weight loss when used regularly.

There have been significant shortage issues with Wegovy, however Lilly, the manufacturer of Zepbound, assures us that it is available for pharmacies to order starting immediately.  The cost can be as low as $25/month for patients who have coverage for the medication.  Representatives from Lilly have informed us that for those who have insurance, but do not have coverage, the monthly cost will be around $500 with their savings coupon.

To find out what your coverage and cost options are for Zepbound, click here.

We are scheduling Zepbound consultations immediately and it should be available at your regular pharmacy, so if you’re interested in trying this promising new weight loss drug, schedule an appointment now!